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CardiomyocyteIn response to stress or injury the heart undergoes a pathological remodeling process, associatedwith hypertrophy,
cardiomyocyte death and ﬁbrosis, that ultimately causes cardiac dysfunction and heart failure. It has become
increasingly clear that signaling events associated with these pathological cardiac remodeling events are regulated
by scaffolding and anchoring proteins, which allow coordination of pathological signals in space and time. A-kinase
anchoring proteins (AKAPs) constitute a family of functionally related proteins that organizemultiprotein signaling
complexes that tether the cAMP-dependent protein kinase (PKA) as well as other signaling enzymes to ensure
integration and processing of multiple signaling pathways. This reviewwill discuss the role of AKAPs in the cardiac
response to stress. Particular emphasis will be given to the adaptative process associated with cardiac hypoxia as
well as the remodeling events linked to cardiac hypertrophy and heart failure. This article is part of a Special
Issue entitled: Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism and Contraction.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular disease culminating in heart failure represents a
leading cause of morbidity and mortality in Western societies. Heart
failure can be triggered by acute or chronic stresses placed on the
myocardium such as myocardial infarction, long-term hypertension,
congenital heart disease, valvular disease and chronic myocarditis
[1,2]. In response to these primary stresses, different compensatory
mechanisms are activated in the damaged heart including hypertrophic
cardiomyocyte growth, ﬁbroblast proliferation and extracellular matrix
deposition [3,4]. This causes the ventricular walls to thicken and
ventricular mass to increase. These myocardial alterations, referred to
as cardiac remodeling, are initially compensatory and contribute to
maintain normal cardiac output [5]. However, in the long term they
can lead to increased cardiomyocyte death and extensive myocardial
ﬁbrosis which can cause severe systolic and diastolic dysfunctions lead-
ing to heart failure [6].
Inwestern societies heart failure is a syndrome that affects about 2%
of the adult population and has an annual incidence of 1% of senior
citizens. Since the ﬁve-year survival rate after diagnosis is lower than
50%,many efforts have beenmade in recent years to unravel themolec-
ular mechanisms underlying this pathology.
It has become increasingly clear that transduction of physiological
and pathological signals in the heart is controlled at the molecularyocyte Biology: Cardiac Path-
logie et de Toxicologie, Rue du
2 5404; fax: +41 21 692 5355.
rights reserved.level by scaffold, anchoring, and adaptor proteins. By positioning sig-
naling enzymes to subcellular sites where they can be accessed by ac-
tivators and, in turn, interact with particular substrate [7,8], these
families of proteins ensure speciﬁcity and coordination of transduc-
tion events.
A-kinase anchoring proteins (AKAPs) are a family a scaffold proteins
that tether the cAMP-dependent protein kinase (PKA) as well as other
signaling enzymes at focal points within the cell to ensure integration
and processing of multiple signaling pathways [9,10]. All AKAPs contain
a PKA anchoring motif consisting of a conserved amphipathic helix
that binds a dimerization and docking domain located in the extreme
N-terminus of the regulatory subunit dimer of PKA [11,12]. Additional
docking motifs located on the anchoring protein allow AKAPs to recruit
additional signaling enzymes including kinases, phosphatases, phospho-
diesterases, adenylyl cyclases, and small molecular weight GTPase to
constitute multienzyme signaling complexes [7]. Subcellular targeting
of individual AKAP signaling complexes at precise subcellular locations
is achieved through specialized protein or lipid binding domains located
on each anchoring protein [13].
2. Anchored PKA signaling in the heart
The cAMP/PKA pathway plays a crucial role in regulating cardiac
contractility under physiological conditions. In this respect, β-
adrenergic mediated PKA activation has been shown to regulate the
phosphorylation and activity of proteins that, directly or indirectly,
control sarcomere contraction and action potential duration. In particu-
lar, phosphorylation of voltage gated L-type Ca2+ channels and
ryanodine receptor 2 (RyR2) enhances Ca2+mobilization from intracel-
lular stores, and favors contraction [14,15], whereas phosphorylation of
phospholamban (PLB), a negative regulator of the activity of the
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reuptake of Ca2+ into the sarcoplasmic reticulum, which favors
myocyte relaxation [16]. On the other hand, phosphorylation of
sarcomeric proteins such as cardiac troponin I (cTnI) and myosin bind-
ing protein C (cMyBP-C) inﬂuences the dynamics of cardiomyocyte
contraction [17–19]. Finally, PKA‐mediated regulation of the delayed
rectiﬁer potassium channelα subunit (KCNQ1) increases the IK current,
accelerates repolarization, and shortens ventricular action potential du-
ration [20].
It is now well established that PKA anchoring through AKAPs plays
an important role in modulating all these cardiac functions. Pioneer
studies using competitor peptides or small molecule compounds that
competitively inhibit the interaction between AKAPs and the regulatory
subunits of PKA indicated that disruption of PKA anchoring reduced the
phosphorylation of cardiac PKA substrates and modiﬁed the kinetic of
cardiomyocyte contraction in response to β-adrenergic stimulation
[21–24]. In recent years, RNA interference and knockout studies have
identiﬁed several AKAP-based transduction complexes involved in the
regulation of calcium cycling and cardiac rhythm. These ﬁndings have
been reviewed extensively in recent years and will not be discussed
further [10,24,25].
In this review article, we will provide an overview of recent litera-
ture describing the role of AKAPs in cardiac pathophysiology. Particular
emphasis will be given to the adaptive process associated with cardiac
hypoxia as well as the remodeling events linked to cardiac hypertrophy
and heart failure.
3. Adaptation to hypoxia
Myocardial oxygen concentration needs to be maintained within a
narrow range to support cardiac function. During ischemic insult, sever-
al adaptivemechanisms are activatedwithin the heart that are aimed at
preserving cardiomyocyte function and integrity in conditions of low
oxygen supply. In this sectionwewill discuss recent evidence highlight-
ing the role of the anchoring proteins mAKAPβ (AKAP6) and AKAP121
(AKAP1) in coordinating signaling enzymes that control the adaptive
response to cardiac hypoxia.
3.1. mAKAPβ (AKAP6)
The transcription factor hypoxia inducible factor 1α (HIF-1α) is a
key regulator of the cellular responses to hypoxia. In normoxia,
HIF-1α is hydroxylated on two speciﬁc proline residues in the
oxygen-dependent degradation domain (ODD) by prolyl hydroxylase
domain proteins (PHDs) [26,27]. Hydroxylated HIF-1α is subsequently
recognized by the von Hippel–Lindau protein (pVHL), which recruits
the Elongin C ubiquitin ligase complex, to ubiquitinate HIF-1α and to
promote its proteasome-dependent degradation [28,29]. Under hypox-
ic conditions, PHDs become inactive because of the lack of sufﬁcient
oxygen. In parallel ubiquitination of PHD proteins by the E3 ubiquitin
ligase seven in absentia homolog 2 (Siah2), marks them for subsequent
degradation by the proteasome machinery [30]. This allows HIF-1α to
escape degradation and to accumulate in the nucleus, where it can di-
merize with HIF-1β to promote the transcription of target genes that
control adaptive responses to hypoxia including angiogenesis, vascular
remodeling, glucose transport, glycolysis, iron transport, cell prolifera-
tion, and cell survival [27,30].
Recent ﬁndings suggest that the muscle speciﬁc anchoring protein
mAKAPβ plays a role in cardiomyocyte oxygen homeostasis by organiz-
ing a multiprotein complex that controls HIF-1α stability. mAKAPβ has
been shown to assemble a signaling complex containing HIF-1α PHD,
pVHL and Siah2 in primary cultures of rat neonatal ventricular
cardiomyocytes (NVMs) (Fig. 1A) [31]. Under conditions of normal
oxygen supply, mAKAPβ-anchored PHD and VHL favor HIF-1α
ubiquitylation and degradation. Under hypoxic conditions, however,
activation of the E3 ligase Siah2 within the mAKAP complex inducesproteasomal degradation of bound PHD. This prevents HIF-1α hydrox-
ylation, ubiquitylation and degradation, and favors HIF-1α-mediated
transcription (Fig. 1A) [31]. Therefore, these ﬁndings indicate that, by
favoring HIF-1α stabilization in response to hypoxia, mAKAPβ en-
hances the transcriptional activation of HIF-1α regulated genes in
cardiomyocytes [31].
mAKAPβ is tethered to the perinuclear membrane of cardiomyocytes
through an interaction with Nesprin-1α suggesting that it functions to
optimally position HIF-1α in proximity of its site of action inside the nu-
cleus, whichmay favor rapid transcriptional regulation in response to di-
minished oxygen availability.
These ﬁndings suggest that mAKAPβ/HIF-1α complex could play an
important role in promoting cardiomyocyte protection during ischemia
arising from partial or complete interruption of coronary blood ﬂow or
myocardial hypoxia that develops as a result of a mismatch between
myocardial oxygen demand and supply during stress-induced hyper-
trophy. In agreement with this assumption, the increased mAKAPβ
expression associated with cardiac hypertrophy could enhance
HIF-1α-mediated transcriptional responses controlling the induction
of glycolysis (which maximizes ATP production under hypoxic condi-
tions), the efﬁciency of mitochondrial respiration and cell survival dur-
ing ischemia [27].3.2. AKAP121 (AKAP1)
Mitochondria constitute themajor source of energy in the heart and
alterations of mitochondrial function and dynamics caused by hypoxia
profoundly impact cardiomyocyte survival. A crucial aspect of mito-
chondrial function is the balance of fusion and ﬁssion (fragmentation),
which impacts mitochondria morphology and activity [32,33]. In this
context, accumulating evidence point to a causative or contributory
role for increased mitochondrial ﬁssion in cardiomyocyte apoptosis
during ischemia [33,34].
At the molecular level, mitochondrial ﬁssion is regulated by
dynamin-related protein 1 (Drp1), a cytosolic GTPase that is recruited
to the surface of mitochondria by the outer membrane protein Fis1
[35,36]. DrpI-mediated GTP hydrolysis provides the driving force
required for mitochondrial membrane ﬁssion [35,36]. Recent evidence
now indicates that the mitochondrial anchoring protein AKAP121 [37]
(also known as D-AKAP1 and AKAP1) plays a crucial role in regulating
DrpI-mediated ﬁssion during hypoxia [38]. AKAP121 controls the
balance between mitochondrial fusion and ﬁssion by forming a com-
plex with DrpI, by favoring PKA-mediated phosphorylation and inacti-
vation of bound DrpI as well as by limiting the formation of DrpI–Fis1
complexes at the mitochondrial surface through a PKA-independent
mechanism that remains to be characterized (Fig. 1B) [38]. Under hyp-
oxic conditions, Siah2 induces AKAP121 ubiquitination and degradation
[38]. As a result, the reduced expression of AKAP121 relieves PKA-
mediated DrpI inhibition and promotes the formation of DrpI–FisI com-
plexes, resulting in mitochondrial ﬁssion and increased apoptosis
(Fig. 1B). In line with these ﬁndings, recent results indicate that dis-
placement of AKAP121 from mitochondria using competitive peptides
promotes mitochondrial dysfunction and induces cardiomyocyte apo-
ptosis in rat hearts [39].
Additional evidence indicates that AKAP121 can inﬂuence cell death
by favoring PKA-mediated phosphorylation of the pro-apoptotic pro-
tein BAD in PC12 and hematopoietic FL5.12 cells [40,41]. This inhibits
the interaction between BAD and the anti-apoptotic protein Bcl2,
which ultimately causes cytochrome C release frommitochondria, acti-
vation of effector caspases and apoptosis [40,41].
Altogether, while the ﬁndings described above indicate that
AKAP121 plays a crucial role in antagonizing apoptotic cardiomyocyte
death in cardiomyocyte cultures, future studies will need to address
whether hypoxia-mediated AKAP121 degradation contributes to
cardiomyocyte death in vivo.
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Fig. 1. AKAPs regulating the cardiac adaptive response to hypoxia. A) Regulation of HIF1α-mediated transcription during normoxia and hypoxia by mAKAP. Under normoxic conditions (left
panel), HIF-1α is hydroxylated on proline residues (Pro402 and Pro564) by PHDand subsequently recognized andubiquitinated by pVHL. UbiquitinatedHIF-1α is targeted to the proteasome for
degradation. Under hypoxic conditions (right panel), PHD is ubiquitinated by Siah2 and targeted to the proteasome. This favors HIF-1α stability, allowing the protein to translocate to the nu-
cleus and forming a heterodimeric complexwithHIF-1β. This leads to transcription of proangiogenic,metabolic and antiapoptotic genes that favor cell survival during hypoxia. B) Involvement
of AKAP121 in regulation of mitochondria dynamics (ﬁssion) during normoxia and hypoxia. Under normoxia (left panel), AKAP121 favors PKA-mediated phosphorylation and inactivation of
bound DrpI and inhibits the formation of DrpI–Fis1-containing ﬁssion complexes at the mitochondrial surface through a PKA-independent mechanism. Under hypoxia (right panel), Siah2
ubiquitinates AKAP121 and reduces its availability. This favors DRP1–Fis1 interaction, which results in mitochondria ﬁssion and cell death.
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Ventricular cardiac hypertrophy is the primary adaptive response
whereby the heart responds to hemodynamic or neurohumoral stresses
[2]. It is associated with an increase in cardiomyocyte size, sarcomere
reorganization and the activation of an embryonic gene program.
Aberrant expression during adult life of fetal proteins involved in cardi-
ac contractility, calcium handling and myocardial energetics leads to
maladaptive changes that, on the long-term, alter contractility and
induce cardiomyocyte death [6].
Mechanical stress has been proposed to promote cardiomyocyte
hypertrophy by activating stretch-sensitive ion channels, integrins,
and other structural proteins in a complex network that links the
extracellular matrix, the cytoskeleton, the sarcomere and the nucleus
[42], as well as by directly activating the angiotensin II receptor in
a ligand-independent manner [43]. On the other hand, many neuro-
humoral stimuli induce cardiac growth by activating G protein
coupled receptors (GPCRs) coupled to the hererotrimeric G protein
Gq, such as the α1-adrenergic- (α1-ARs), angiotensin-II- (AT1-Rs)
and endothelin-1-receptors (ET1-Rs) [44]; or Gs, such as the
β-adrenergic receptors (β-ARs) [45].
Evidence collected over the last seven years indicates that AKAPs
play a central role in coordinating multiple pro-hypertrophic signal-
ing pathways activated by stress stimuli. In particular, mAKAPβ and
AKAP-Lbc have been identiﬁed as organizers of multienzyme trans-
duction complexes promoting cardiomyocyte hypertrophy [46–48],whereas AKAP121 has been identiﬁed as a negative modulator of
stress-induced hypertrophic signaling [49]. These ﬁndings are described
below.
4.1. mAKAPβ (AKAP6)
The mAKAPβ is a perinuclear anchoring protein that coordinates
multiple pathways controlling cardiomyocyte hypertrophy in response
to extracellular stimuli including catecholamines, endothelin and cyto-
kines. In this context, RNA interference studies performed in NVMs
indicate that mAKAP knockdown signiﬁcantly reduces hypertrophy
and fetal gene expression induced by the activation of endogenous
α1- and β-adrenergic receptors (ARs), Endothelin1-receptors (ET1-Rs)
and gp130/leukemia inhibitor factor (LIF) receptors [45,46]. At the
perinuclear membrane, mAKAPβ recruits a repertoire of multiple signal-
ing enzymes that control hypertrophic gene transcription through at
least three mechanisms.
The ﬁrst, requires the formation of a complex between mAKAPβ,
PKA, RyR2, calcineurin Aβ (CaNAβ) and the pro-hypertrophic tran-
scription factor NFATc3 [47]. In response to β-AR activation, anchored
PKA promotes RyR2 phosphorylation. The consequent release of Ca2+
is proposed to activate bound CaNAβ, which, in turn, dephosphory-
lates NFATc3 and promotes its nuclear translocation, thus favoring
hypertrophic gene transcription (Fig. 2A) [47,50].
The second, requires the interaction with phosphodiesterase 4D3,
which, in turn recruits the cAMP-activated guanine nucleotide
mAKAP
NFATc3 NFATc3
P
CaNA
?
PKA PLC-
IP3
Ca2+
?
AC5G s
cAMP
PDE4D3Ep
ac
1
ERK5
MEK5
MEKK
P
Rap1
PP2A
ET1-R-AR1-AR
gp-130
LIF-R
A
1-AR/ET1-R
PKA
B
AKAP
Lbc
PKC
P
14-3-3
1-AR
Rho
GDP
Rho
GTP
mAKAP AKAP-Lbc
G 12G q
Transcription of hypertrophic genes
RyR2
P
Ca2+
Cytoplasm
Nucleus
Nesprin1
Transcription of
hypertrophic genes
Cytoplasm
Nucleus
PKD
P
PP
PKD
P
PP
HDAC5
P P
HDAC5
P P
HAT
Ac Ac
Transcription
Factors
(MEF2)
p38/ERK?
Fig. 2. AKAPs regulating cardiac hypertrophy. A) mAKAPβ assembles a multivalent transduction complex localized at the outer nuclear membrane of cardiomyocytes that integrates hy-
pertrophic signals from multiple membrane receptors including β-ARs, α1-ARs, ET1‐Rs and LIF/gp130-Rs. β-Adrenergic stimulation generates cAMP, through the activation of
mAKAPβ-associated AC5. The raise in cAMP concentration activates anchored PKA, leading to the phosphorylation of RyR2 and to an increased release of Ca2+ from intracellular stores.
Thismight locally activate mAKAP-bound CaNAβ leading to the dephosphorylation and nuclear translocation of the transcription factor NFATc3whatwill induce hypertrophic gene tran-
scription. Anchored PKA can also phosphorylate additional enzymes within the mAKAPβ complex including PDE4D3 and AC5 and PP2A. Phosphorylation of PDE4D3 and AC5 enhances
local cAMP degradation and inhibits cAMP synthesis, respectively, whereas phosphorylated PP2A promotes PDE4D3 dephosphorylation favoring cAMP signaling. In response to ET1‐Rs
stimulation, mAKAPβ-bound PLC-ε promotes cardiomyocyte hypertrophy via an unknown pathway that may involve inositol-1,4,5-triphosphate production, mobilization of local
Ca2+ stores, and activation of mAKAP-bound CaNAβ. Stimulation of LIF/Gp130-Rs and α1-ARs activates hypertrophic MEK5-ERK5 signaling. mAKAP-anchored ERK5 is proposed to pro-
mote cardiomyocyte hypertrophy through the activation of MEF2 and/or through the inhibition of PDE4D3 and the consequent stimulation of the cAMP-PKA-Ryr2-calcineurin-NFATc3
pathway described above. High cAMP concentrations inhibit anchored ERK5 through a feedbackmechanism that requires activation of Epac and its effector Rap1. B) The Rho-GEF activity
of AKAP-Lbc is enhanced byα1-ARs through a Gα12-dependent pathway. Activated RhoA promotes cardiomyocytes hypertrophy through signaling cascades that are yet to be character-
ized. Possible effector pathwaysmight involve p38 and ERK. Phosphorylation of AKAP-Lbc on serine-1565 by anchored PKA induces the recruitment of 14-3-3, which inhibits the Rho-GEF
activity of AKAP-Lbc. AKAP-Lbc also serves a scaffold for PKCη and its downstream effector PKD. Anchored PKCη is activated in response toα1-ARs and ET1Rs stimulation and phosphor-
ylates PKD. In turn, PKD translocates to the nucleus where it promotes HDAC5 phosphorylation and nuclear export favoring MEF2-dependent transcription of fetal genes.
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kinase (MAPK) ERK5 and its upstream activator MEK5 [46]. Activation
of gp130 by LIF stimulates MEK5–ERK5 signaling (Fig. 2A). It is not
entirely clear how anchored ERK5 favors cardiac hypertrophy. One
possibility is that it could favor the phosphorylation and nuclear activa-
tion of MEF2 [51]. Alternatively, ERK5 mediated inhibition of PDE4D3
could increase the local concentration of cAMP, and, as a consequence
enhance the PKA–Ryr2–calcineurin–NFATc3 pathway described above
(Fig. 2A) [47]. High cAMP concentrations inhibit anchored ERK5
through a feedback mechanism that requires activation of Epac and its
effector Rap1 (Fig. 2A) [46].
Interestingly, PDE4D3 plays an important role in regulating cAMP
levels in the vicinity of the anchoring protein. When cAMP concentra-
tions rise, anchored PKA phosphorylates and activates PDE4D3, which
depletes the local concentrations of cAMP and enables reformation of
the inactive PKA holoenzyme [46,52]. This implies that the mAKAP
complex generates cyclic pulses of PKA activity (Fig. 2A).
The third mechanism whereby mAKAPβ regulates cardiomyocyte
hypertrophy involves the recruitment of phospholipase C-ε (PLC-ε).
This was mainly demonstrated by RNA silencing experiments showing
that disruption of mAKAP–PLC-ε complexes in rat NVMs attenuates
endothelin 1-induced hypertrophy [53]. It is currently unknown how
anchored PLC-ε promotes hypertrophy but possible mechanisms
might involve the local formation of inositol 1,4,5‐phosphate, whichcould mobilize intracellular Ca2+ and promote the activation of
mAKAPβ-bound CaNAβ and NFATc3 (Fig. 2A). This might lead to
NFATc3 dephosphorylation and nuclear translocation, and favor hyper-
trophic gene transcription.
Collectively, theseﬁndings indicate that themAKAPβ signaling com-
plex coordinates signals emanating from diverse membrane receptors
to favor NFAT-dependent hypertrophic gene transcription.
4.2. AKAP-Lbc (AKAP13)
AKAP-Lbc is a cardiac anchoring protein that integrates signals from
multiple membrane receptors and conveys them to the activation of
transcriptional responses that ultimately regulate the expression of
genes associated with hypertrophy [54].
AKAP-Lbc acts as a RhoA selective guanine nucleotide exchange
factor (GEF) [55] and serves as a scaffold for multiple signaling
enzymes. RhoA activation is mediated by a GEF module constituted
of consecutive Dbl (DH) and pleckstrin homology (PH) domains [55].
In cardiomyocytes, AKAP-Lbc Rho-GEF activity is enhanced by α1-ARs
through a transduction cascade involving the α subunit of the
heterotrimeric G protein G12 (Fig. 2B) [48,55].
Silencing of AKAP-Lbc expression or inhibiting Gα12 function in rat
NVMs strongly reduces both α1-AR-mediated RhoA activation and
hypertrophic responses [48,56]. This suggests that this anchoring
905D. Diviani et al. / Biochimica et Biophysica Acta 1833 (2013) 901–908protein coordinates a pro-hypertrophic transduction pathway activated
by theα1-AR that includes Gα12, AKAP-Lbc and RhoA (Fig. 2B).While it
is currently unknownwhich Rho effector moleculesmediate the hyper-
trophic effect of AKAP-Lbc in cardiomyocytes, recent studies performed
in cell lines indicate that the anchoring protein can recruit signaling en-
zymes involved in the activation of different mitogen activated protein
kinase (MAPK) pathways [57,58]. In particular, AKAP-Lbc has been
shown to assemble a transduction complex containing the scaffold ki-
nase suppressor of Ras (KSR-1), Raf and MEK1/2, that coordinates the
activation of ERK1/2 [57]; and to mobilize a signaling unit that includes
the RhoA effector PKNα, MLTK, MKK3 and p38α, which promotes RhoA
dependent activation of p38α [58]. Given the importance of ERK1/2- and
p38α-mediated pathways in regulating cardiomyocyte growth in vivo
[59,60], it will be crucial to deﬁnewhether formation of these complexes
within the heart can inﬂuence the hypertrophic response to stress
stimuli.
In addition to its RhoA-mediated effects on cardiomyocyte growth,
additional ﬁndings demonstrate that AKAP-Lbc also coordinates a
protein kinase D (PKD) pathway regulating the expression of fetal
genes (Fig. 2B) [56,61]. In particular, AKAP-Lbc can recruit protein
kinase Cη (PKCη) and its downstream effector PKD. In response to
phenylephrine or endothelin I stimulation, anchored PKCη phosphory-
lates and activates PKD, which, after being released from the AKAP-Lbc
complex, can induce phosphorylation of histone deacetylase 5 (HDAC5)
to promote its nuclear export [56]. This is proposed to lead to chromatin
derepression and to favor myocyte enhanced binding factor 2 (MEF-2)-
dependent transcription of hypertrophic genes (Fig. 2B). Accordingly,
downregulation of AKAP-Lbc expression in rat NVMs suppressed the
nuclear export of HDAC5 and repressed transcription of the atrial natri-
uretic factor (ANF) gene, a marker for pathological cardiac hypertrophy
[56].
Recent evidence indicates that AKAP-Lbc anchors PKA to favor
β-adrenergic receptor-mediated phosphorylation of the heat shock
protein 20 (HSP20) in cardiomyocytes [62]. Knowing that PKA-
mediated phosphorylation of HSP20 can protect against hypertrophy
[63], one could raise the hypothesis that AKAP-Lbc might also coordi-
nate anti-hypertrophic pathways.
Importantly, AKAP-Lbc expression is strongly increased in the
heart of mice submitted to neurohumoral or hemodynamic stresses
including chronic infusion of phenylephrine [48], angiotensin II and
thoracic aortic constriction (A. Appert-Collin and D. Diviani,
unpublished observations). In line with these ﬁndings, analysis of
AKAP-Lbc expression in heart samples from patients with hypertro-
phic cardiomyopathy revealed a twofold increase in the AKAP-Lbc
mRNA content over normal patient control samples [56], suggesting
a possible role for the anchoring protein in regulating pathological
cardiac remodeling. However, direct in vivo evidence for an implica-
tion of AKAP-Lbc in cardiac hypertrophy is currently lacking mainly
because AKAP-Lbc knockout mice die in utero due to heart develop-
mental defects [64]. Future experiments using knock-in and/or tissue
speciﬁc inducible knockout models will likely solve this problem and
elucidate the relative contribution of the multiple signaling pathways
activated by the anchoring protein in this heart pathology. One could
also speculate that interfering with the ability of AKAP-Lbc to activate
RhoA and/or to interact with PKD might represent a potential inter-
esting strategy to reduce cardiac hypertrophy in vivo.
4.3. AKAP121 (AKAP1)
Recent evidence suggests that AKAP121 functions as negative regu-
lator of cardiomyocyte hypertrophy. Knockdown of AKAP121 expres-
sion by RNA interference in rat NVMs promotes cardiomyocyte
growth, whereas its overexpression reduces both basal cardiomyocyte
size and the pro-hypertrophic effects of the β-adrenergic agonist iso-
proterenol [49]. At the molecular level, these effects can be explained
by the fact that AKAP121 can sequester and inhibit the phosphatasecalcineurin. This affects the downstream activation of the transcription
factor NFAT, which requires calcineurin-mediated dephosphorylation
in order to translocate from the cytoplasm to nucleus and activate target
hypertrophic genes [49]. Consistent with a role of AKAP121 in
cardiomyocyte growth inhibition, induction of hypertrophy in rats by
aortic banding strongly reduces the ventricular expression of the an-
choring protein [39].
Based on these ﬁndings, one could postulate that AKAP121 degra-
dation induced by hypoxia (Fig. 1A) would release calcineurin, and, as
a consequence promote activation and nuclear translocation of NFAT.
This could potentially provide a mechanistic explanation for the
well-established stimulatory effect of hypoxia on cardiac hypertro-
phy. Future studies will need to address whether alterations of the
cardiac expression of this anchoring protein can affect the develop-
ment of cardiac hypertrophy and dysfunction.
5. Heart failure
Heart failure represents the end phenotype of a number of diverse
primary pathologies that include hypertension, coronary artery disease,
diabetes and valvular diseases. It is associated with diminished
cardiomyocyte contractility, cardiomyocyte apoptosis, ﬁbrosis and re-
duced ejection fraction. Depressed cardiac function causes reﬂex sym-
pathetic activation [2]. The consequent release of high levels of
catecholamines from sympathetic nerve endings promotes desensitiza-
tion, internalization and degradation of cardiac β-adrenergic receptors,
and inhibits downstream PKA signaling [65]. This attenuates the stimu-
latory effects of PKA on calcium cycling and reduces contractility [65].
The process of β-AR desensitization and internalization is initiated
by the G protein-coupled receptor kinase 2 (GRK2), which phosphory-
lates ligand-occupied receptors thus favoring the binding of β-arrestin
and the adaptor protein complex 2 (AP2), two proteins that mediate
the recruitment of clathrin [66–68]. Importantly, GRK2 and AP2 can
also bind the phosphoinositide 3-kinase γ (PI3Kγ) and promote its re-
cruitment to the plasmamembrane in proximity of the β-adrenergic re-
ceptor [69]. At this location PI3Kγ promotes local PIP3 production,
which favors receptor internalization. It is now shown that PI3Kγ
forms a complex with PKA that regulates β-AR signaling and internali-
zation in cardiomyocytes [70]. Under physiological conditions, the acti-
vation of PI3Kγ-anchored PKA by the β-AR/cAMP pathway leads to the
phosphorylation of PI3Kγ. This inactivates the kinase and tonically in-
hibits receptor internalization (Fig. 3, left panel) [70]. During heart fail-
ure, PI3Kγ is dramatically upregulated, thus limiting the formation of
complexes containing PKA. As a result, PI3Kγ escapes PKA-mediated in-
activation, decreases cell surface expression of β-ARs and depresses
heart function (Fig. 3, right panel). In line with these ﬁndings, pharma-
cological inhibition of PI3Kγ restores β-AR density and improves con-
tractility in failing hearts [70]. This suggests that targeting the PI3Kγ
signaling complexes might emerge as a potential therapeutic approach
aimed at normalizing myocardial function during heart failure.
While it is clear that downregulation of β-ARs contributes impor-
tantly to depressed cardiac function during heart failure, it is of par-
ticular importance to determine whether altered AKAP signaling
could also contribute to the profound decrease in PKA activation ob-
served at end-stage heart failure. This hypothesis is consolidated by
the ﬁndings by Zakhary et al., who showed that the interaction be-
tween AKAPs and R subunits of PKA is decreased in failing hearts
[71]. This might potentially have important functional consequences
since experimental disruption of AKAP–PKA complexes in rat NVMs
using competitor peptides corresponding to the regulatory subunit-
binding domain of AKAPs can decrease PKA-dependent phosphoryla-
tion of RyR2, phospholamban, cTnI and cMyBPC, inhibit cAMP-
mediated regulation of L-type Ca2+ currents, and alter the kinetics
of cardiomyocyte contraction in response to β-adrenergic stimulation
[21–24]. Based on this experimental evidence, it will be crucial to de-
termine whether individual AKAP complexes are altered during the
Inhibition of PIP3 formation
and -AR internalization
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p110
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cAMP
p110
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p87
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AR
p110
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Fig. 3. The role of PI3Kγ–PKA complexes in heart failure. Under physiological conditions, the myocardial PI3Kγ catalytic subunit p110γ forms a complex with the adaptor subunits p84/p87,
PDE3B and PKA. Anchored PKA activates PDE3B to enhance cAMPdegradation and phosphorylates p110γ to inhibit its lipid kinase activity andmaintainβ-ARs at the surface of cardiomyocytes.
In heart failure, however, upregulation of p110γ uncouples the lipid kinase from PKA. This leads to decreased PKA-mediated p110γ inhibition, which enhances β-ARs internalization andmyo-
cardial dysfunction.
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inﬂuences the progression of the disease.
6. Conclusions and perspectives
It has become increasingly clear that the aspects of intracellular
signaling inﬂuencing heart pathophysiology are regulated by cardiac
AKAPs, which assemble macromolecular complexes at deﬁned subcel-
lular compartments to provide tight spatiotemporal control to stress
signal transmission.
While over the past ten years AKAPs have emerged as key molec-
ular regulators of the cardiac response to injury and stress, more work
is required to precisely deﬁne the global implication of this family of
anchoring proteins in the remodeling process sustained by the
stressed heart. In this respect, it will be crucial to determine whether
AKAPs could play a role in cardiac ﬁbrosis and in the remodeling of
cardiac metabolism, as several experimental evidence now suggests
a key role for PKA in the regulation of cardiac ﬁbroblast functions,
such as migration and collagen secretion [72], and metabolic process-
es including glycolysis and oxidative phosphorylation [73–75].
While in past years AKAP function has been mainly studied in iso-
lated cardiomyocytes, a growing number of recent studies now sug-
gest that AKAP-based signaling complexes organize physiologically
relevant signaling events also in vivo. The generation of inducible car-
diac speciﬁc knock-out and/or knock-in animal models will certainly
expand our current knowledge of how anchoring proteins organize
and integrate signaling pathways that inﬂuence heart function under
both physiological and pathological conditions. They will also provide
precious tools to dissect the relevance of individual protein–protein in-
teractions inheartpathophysiology. This informationtogetherwith the
accurate structural analysis of relevant interactive surfaces withinAKAP transduction complexes will be instrumental for designing and
developing peptides and small molecule inhibitors that could antago-
nize AKAP-mediated pathological processes in the remodeling heart.Acknowledgements
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